We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zymeworks Inc. (ZYME) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Zymeworks Inc. (ZYME - Free Report) closed at $8.63 in the latest trading session, marking a +1.89% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.7%. Elsewhere, the Dow lost 0.87%, while the tech-heavy Nasdaq added 2.77%.
Prior to today's trading, shares of the company had lost 4.83% over the past month. This has lagged the Medical sector's loss of 4.27% and was narrower than the S&P 500's loss of 5.06% in that time.
Zymeworks Inc. will be looking to display strength as it nears its next earnings release. In that report, analysts expect Zymeworks Inc. to post earnings of -$0.53 per share. This would mark year-over-year growth of 55.46%. Meanwhile, our latest consensus estimate is calling for revenue of $10.75 million, up 459.9% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.94 per share and revenue of $46.43 million, which would represent changes of -202.11% and -88.74%, respectively, from the prior year.
Any recent changes to analyst estimates for Zymeworks Inc. should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 36.66% lower. Zymeworks Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 100, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zymeworks Inc. (ZYME) Gains As Market Dips: What You Should Know
Zymeworks Inc. (ZYME - Free Report) closed at $8.63 in the latest trading session, marking a +1.89% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.7%. Elsewhere, the Dow lost 0.87%, while the tech-heavy Nasdaq added 2.77%.
Prior to today's trading, shares of the company had lost 4.83% over the past month. This has lagged the Medical sector's loss of 4.27% and was narrower than the S&P 500's loss of 5.06% in that time.
Zymeworks Inc. will be looking to display strength as it nears its next earnings release. In that report, analysts expect Zymeworks Inc. to post earnings of -$0.53 per share. This would mark year-over-year growth of 55.46%. Meanwhile, our latest consensus estimate is calling for revenue of $10.75 million, up 459.9% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.94 per share and revenue of $46.43 million, which would represent changes of -202.11% and -88.74%, respectively, from the prior year.
Any recent changes to analyst estimates for Zymeworks Inc. should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 36.66% lower. Zymeworks Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 100, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.